Home › Research › Inflammation and the immune system
Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years
McGeer PL, Rogers J, McGeer EG.. Journal of Alzheimer's disease : JAD, 2006-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Two basic discoveries have spurred research into inflammation as a driving force in the pathology of Alzheimer disease (AD). The first was the identification of activated microglia in association with the lesions. The second was the finding that rheumatoid arthritics were relatively spared from the disease.
What this study adds
Evidence grade: Low
This is a narrative review. This review notes that a pilot trial showed promise for indomethacin as a useful therapeutic agent in Alzheimer's disease but that appropriate follow-up trials have not been done. It reports no established treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
McGeer, P. L., Rogers, J., & McGeer, E. G. (2006). Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. Journal of Alzheimer's disease : JAD. https://doi.org/10.3233/jad-2006-9s330
Vancouver
McGeer PL, Rogers J, McGeer EG. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. Journal of Alzheimer's disease : JAD. 2006. doi:10.3233/jad-2006-9s330. PMID: 16914866.
BibTeX
@article{mcgeer2006-16914866,
author = {McGeer, P. L. and Rogers, J. and McGeer, E. G.},
title = {{Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years}},
journal = {Journal of Alzheimer's disease : JAD},
year = {2006},
doi = {10.3233/jad-2006-9s330},
pmid = {16914866},
url = {https://doi.org/10.3233/jad-2006-9s330}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The first was the identification of activated microglia in association with the lesions.
- The second was the finding that rheumatoid arthritics were relatively spared from the disease.
- These findings spurred the first pilot trial of a classical NSAID in the treatment of AD.
- This trial showed promise for indomethacin as a useful therapeutic agent but appropriate follow up trials have not been done.
Why it matters
This review notes that a pilot trial showed promise for indomethacin as a useful therapeutic agent in Alzheimer's disease but that appropriate follow-up trials have not been done. It reports no established treatment, cure, or prevention.
Study details
- Evidence strengthLow
How this study scored 44/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2006 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 227 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.3 citations a year over 22 year(s) since 2006 |
| Impact for its field and year | 4 / 6 | Cited 13.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Edith G. McGeer: h-index 103 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of British Columbia: institution h-index 1,424 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 16914866) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Inflammation and the immune system from nearby years
Also in Inflammation and the immune system
138 studies in the library are filed under Inflammation and the immune system with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Inflammation and the immune system hub.